{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-33638863-abaloparatide:v1","objectPathId":"pubmed-pmid-33638863-abaloparatide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-33638863-abaloparatide/","json":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-33638863-abaloparatide-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-33638863-abaloparatide-v1.md"},"story":{"slug":"pubmed-pmid-33638863-abaloparatide","version":1,"domain":"Literature metadata","dateInSource":"2024-03-31","sourceCheckedAt":"2026-07-30","publishedAt":"2026-08-13","peptideSlugs":["abaloparatide"],"peptides":[{"slug":"abaloparatide","url":"https://peptidescanner.com/peptides/abaloparatide/"}]},"claims":[{"id":"headline","text":"Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density.","sourceIds":["pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e"]},{"id":"summary","text":"PubMed lists PMID 33638863 in Clinical drug investigation as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2021-02-27 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e"]},{"id":"paragraph-1","text":"PubMed lists PMID 33638863 in Clinical drug investigation as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2021-02-27 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e"]}],"sources":[{"id":"pubmed-observation-pmid-33638863-2024-03-31-7d0404213a0e","name":"PubMed","sourceClass":"A","title":"Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density. · retained source version 1:2024-03-31:current:7d0404213a0e8fa90c0adc92e9249edc2eae1da988a7357d53aeffa63c7c4166","url":"https://pubmed.ncbi.nlm.nih.gov/33638863/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"fe860d2146ed04554b997cfea1185b9cc18fb2d9d08660c08dd49fec01d5cd15","tierARecordSha256":"2ddc77ae76fc4d21bdea763d9e73fc2a47b078029a7a22d63cfc0ba69e68966b"},"integrity":{"algorithm":"sha256","contentSha256":"1c90a5c559bfc96b3c09f58ac23cfde4f6b4b1c8ad1fec14bea7ddf5993ad9ee"}}